A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513992-42-00

Acronym

ANT-008

Enrollment

677

Registered

2024-07-29

Start date

2022-09-13

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer

Brief summary

Time to first event of centrally adjudicated VTE recurrence 6 months post randomization

Interventions

DRUGFragmin® 5000 IU

DRUGAbelacimab 150 mg/ml solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to first event of centrally adjudicated VTE recurrence 6 months post randomization	—

Countries

Austria, Czechia, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Norway, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026